View the replay of the Cerus Industry Workshop at the 2020 SCABB (South Central Association of Blood Banks) Virtual Meeting.
Are You Ready for FDA’s Bacterial Contamination Guidance?
FDA has called for new measures via a final guidance to minimize the risk of bacterial contamination. Blood centers and/or hospitals may need to implement a compliant method to address platelet transfusion safety within a defined time. This workshop will provide an overview, including economic considerations of the different strategies recommended by FDA’s final guidance on bacterial contamination in platelets. Further perspectives will be presented on the role that pathogen reduction plays in complying with FDA guidance, and in meeting the needs of blood centers and hospitals who strive to deliver timely, safe and efficacious products to meet patient needs.
Platelet Availability and Economic Impact of Bacterial Risk Reduction Strategies
Vera Chrebtow, MBA
Sr. Director of Global Marketing
Streamlining Operational Efficiency with Pathogen Reduction – A Blood Center Perspective
Alicia Prichard, MT (ASCP), SBB, MBA
Sr. Vice President, Biologics, Labs and Supply Chain
St. Petersburg, FL
Prescribing Pathogen Reduced Components in the Hematology-Oncology Setting – A Hospital Perspective
Harold Alvarez, MD
Medical Director, Blood and Bone Marrow Transplant Laboratory
Baptist South Miami Cancer Institute